Boston Scientific Corporation BSX is scheduled to ... Access solutions products, POLARx FIT and WATCHMAN FLX. Performance in China is expected to have been led by the company’s advanced ...

Analyst Mike Matson highlighted that the growth story for Boston Scientific depends heavily on its cardiac implant, Watchman. Watchman is a medical device that's effectively designed to reduce the ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

Analyst Mike Matson's neutral thesis is mainly based on Boston Scientific's (NYSE:BSX) cardiac implant, Watchman, for which a ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

The OPTION trial is a significant study for Boston Scientific as it evaluates the potential market expansion for its left-atrial-appendage-closure (LAAC) device, WATCHMAN, which is projected to ...

Warning! GuruFocus has detected 5 Warning Sign with BSX. Analyst Mike Matson highlighted that the growth story for Boston Scientific depends heavily on its cardiac implant, Watchman. Watchman is a ...

Boston Scientific Corporation reported 19.3% y/y ... Regulatory approvals and trials, particularly for WATCHMAN FLX Pro and FARAPULSE, are crucial for future performance and could introduce ...